CorMedix shares jumped 15% after Q2 results beat estimates on revenue strength, supported by solid DefenCath utilization and contributions from its Melinta portfolio.
CorMedix shares jumped 15% after Q2 results beat estimates on revenue strength, supported by solid DefenCath utilization and contributions from its Melinta portfolio.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
